Showing results (121-130 of 183) with videos related to
Sort By:
Pageof 19
AIDS Research and Human Retroviruses|July 14, 2010
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trialJosé M Miró, Christian Manzardo, Judith Pich, et al.Current HIV Research|November 26, 2009
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, SpainBeatriz Mothe, Iñaki Perez, Pere Domingo, et al.AIDS (London, England)|June 22, 2022
Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIVLaura Donadeu, Juan Manuel Tiraboschi, Sofía Scévola, et al.Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.Antiviral Therapy|June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravirJosé L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.Open Forum Infectious Diseases|January 28, 2025
Using Anal Cytology and Human Papillomavirus DNA and E6/E7 mRNA Detection to Optimize High-Resolution Anoscopy Referrals in Men Who Have Sex With Men With HIVAna C Silva-Klug, Sònia Paytubi, Montserrat Torres, et al.The Journal of Antimicrobial Chemotherapy|April 12, 2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 studyMaria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohortJuan Berenguer, María Jesús Pérez-Elías, José María Bellón, et al.Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.Pageof 19